Latest News
Medicare will cover weight-loss drugs - Axios
Medicare will cover weight-loss drugs under a new deal with drugmakers Eli Lilly and Novo Nordisk. Approximately 10 percent of Medicare enrollees who meet certain medical criteria, such as a diagnosis of obesity or related health conditions, will be eligible for coverage of GLP-1, Ozempic, and Zepbound. Novo Nordisk stated the expanded Medicare coverage will be available through a pilot program. Maya Goldman, writing for Axios, reports on this new Medicare coverage. Read Ms. Goldman’s article here…
This posting is presented for informational purposes only and does not represent legal or financial guidance. Any opinions or interpretations presented are either those of the original author or, in the case of articles authored by the AMAC Foundation, are the opinions of AMAC Foundation staff, originally trained and accredited by the National Social Security Association (NSSA) and certified via the AMAC Foundation. Any links included in the article are valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the links’ validity. NSSA and the AMAC Foundation and its staff are not affiliated with or endorsed by the Social Security Administration or any other governmental entity. To submit a question, visit our website (https://amacfoundation.org/services/) or email us at ssadvisor@amacfoundation.org. Because we are a non-profit organization, there is no charge for these services.
